Peijia Medical (Suzhou) Co., Ltd.
沛嘉医疗
Peijia Medical (Suzhou) Co., Ltd.
Biotech/Healthcare
Peijia Medical's TaurusOne has completed clinical trials and is expected to obtain medical device registration and launch in 2020. The company is developing its second-generation aortic valve product as well as mitral and tricuspid valve products, which will soon enter the clinical stage.
Latest round: IPO (2020)
Source: ChinaBulls — chinabulls.com
Last updated 2020-05-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.